Brief: Lee's Pharmaceutical Obtained Approval From CDE Of China's NMPA For Socazolimab
27/09/2021 16:20
Sept 27 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* OBTAINED APPROVAL FROM CENTER FOR DRUG EVALUATION OF
CHINA'S
NMPA TO SUBMIT NEW DRUG APPLICATION FOR SOCAZOLIMAB
Source text for Eikon: ID:nHKS7fPCZk
Further company coverage: 0950.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA